Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Sarepta Therapeutics (SRPT)
Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,454,378
  • Shares Outstanding, K 87,982
  • Annual Sales, $ 933,010 K
  • Annual Income, $ -703,490 K
  • 60-Month Beta 0.97
  • Price/Sales 12.11
  • Price/Cash Flow N/A
  • Price/Book 29.27
Trade SRPT with:

Options Overview Details

View History
  • Implied Volatility 47.27% ( -4.54%)
  • Historical Volatility 86.28%
  • IV Percentile 18%
  • IV Rank 24.57%
  • IV High 74.92% on 07/01/22
  • IV Low 38.26% on 12/20/22
  • Put/Call Vol Ratio 0.29
  • Today's Volume 1,512
  • Volume Avg (30-Day) 5,431
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 82,425
  • Open Int (30-Day) 69,203

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -1.41
  • Number of Estimates 5
  • High Estimate -0.99
  • Low Estimate -1.60
  • Prior Year -1.20
  • Growth Rate Est. (year over year) -17.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
117.11 +11.17%
on 03/17/23
159.84 -18.55%
on 03/06/23
+7.13 (+5.79%)
since 02/24/23
3-Month
116.10 +12.14%
on 01/09/23
159.84 -18.55%
on 03/06/23
+0.24 (+0.18%)
since 12/23/22
52-Week
61.28 +112.45%
on 06/16/22
159.84 -18.55%
on 03/06/23
+49.75 (+61.85%)
since 03/24/22

Most Recent Stories

More News
SRPT INVESTOR NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of...

SRPT : 130.19 (+1.41%)
3 Up-and-Coming Growth Stocks to Buy Right Now

These companies are small now but could grow much larger over time.

AXSM : 61.96 (-0.08%)
SRPT : 130.19 (+1.41%)
TVTX : 20.88 (+2.45%)
SRPT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sarepta Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Robbins Geller Rudman & Dowd LLP announces an investigation into potential violations of U.S. federal securities laws by Sarepta Therapeutics, Inc. (NASDAQ: SRPT) focused on whether Sarepta and certain...

SRPT : 130.19 (+1.41%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such...

SRPT : 130.19 (+1.41%)
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Sarepta Therapeutics, Inc. (SRPT) Investigation

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Investors...

SRPT : 130.19 (+1.41%)
Why did Sarepta Therapeutics Stock Plummet?

SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.

SRPT : 130.19 (+1.41%)
BMRN : 90.74 (+0.70%)
PFE : 40.39 (+0.52%)
PTC : 121.70 (+1.43%)
FGEN : 18.15 (-2.79%)
PTCT : 44.17 (-5.36%)
Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...

SRPT : 130.19 (+1.41%)
BNTX : 128.20 (-0.92%)
INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of...

SRPT : 130.19 (+1.41%)
Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001

Sarepta Therapeutics' (SRPT) shares plunged almost 20% as the FDA decides to hold an advisory meeting for the BLA of its lead gene therapy candidate SRP-9001.

SRPT : 130.19 (+1.41%)
KALA : 15.57 (+6.43%)
CERT : 23.65 (+1.15%)
JSPR : 2.00 (+3.09%)
The 2 Stocks to Watch on a Nail-Biter Friday

Investors are preparing for a volatile day.

$SPX : 3,970.99 (+0.56%)
FDX : 217.60 (+0.31%)
SRPT : 130.19 (+1.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a...

See More

Key Turning Points

3rd Resistance Point 135.04
2nd Resistance Point 132.79
1st Resistance Point 131.49
Last Price 130.19
1st Support Level 127.94
2nd Support Level 125.69
3rd Support Level 124.39

See More

52-Week High 159.84
Last Price 130.19
Fibonacci 61.8% 122.19
Fibonacci 50% 110.56
Fibonacci 38.2% 98.93
52-Week Low 61.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar